Feel more energized throughout the day with improvements in movement, stamina, and daily performance
Retatrutide is projected to complete Phase 3 through 2026 and file for approval immediately after
GLP-1 receptor agonists led with 38.55% share in 2025
Why Biomarkers and Metabolic Testing Matter Before Starting GLP-1 Therapy Before initiating GLP-1 treatment, assessing baseline fasting glucose, HbA1c, lipid panels, and inflammatory markers provides essential context
If you need to skip a dose occasionally due to your schedulelike when you're going on vacation and need to drive late at nightyou can adjust your dosage accordingly
This plateau typically occurs after 4 to 5 weeks of treatment, and it is when most patients experience the most predictable appetite control and consistent weight loss momentum